UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware	0-21696	22-3106987
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

26 Landsdowne Street, Cambridge, Massachusetts	02139
(Address of principal executive offices)	(Zip Code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

⃞    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In a press release dated March 16, 2010, ARIAD Pharmaceuticals, Inc. (the “Company”) announced financial results for the fourth quarter and year ended December 31, 2009. A copy of the press release is attached hereto as Exhibit 99.1. The information under the headings “Financial Highlights” and “Today’s Conference Call Reminder” and the condensed consolidated financial statements included in the press release are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

In the press release dated March 16, 2010, the Company also provided information on upcoming medical and investor meetings. The information set forth under the headings “Upcoming Medical Meeting” and “Upcoming Investor Meeting” in the press release is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

In the press release dated March 16, 2010, the Company also provided information on the status and expected timing of its SUCCEED trial, progress in its AP24534 program and negotiations with Merck regarding revisions to the parties’ collaboration agreement. The information set forth under the headings “Phase 3 Sarcoma Data in 2010,” “Advancing AP24534 to a Pivotal Trial,” “AP24534 Data Highlights from ASH” and “Progress in Negotiations with Merck” is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Exhibit
Number		Description

99.1		Press release dated March 16, 2010.

The portions of the press release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the press release are being furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ARIAD Pharmaceuticals, Inc.


	By:	/s/ Edward M. Fitzgerald
		Edward M. Fitzgerald
		Senior Vice President, Chief Financial Officer